Navigation Links
Renal Solutions, Inc. Announces FDA 510(k) Clearance of New Design of the Allient(R) Sorbent Hemodialysis System for Chronic and Acute Hemodialysis
Date:10/22/2007

WARRENDALE, Pa., Oct. 22 /PRNewswire/ -- Renal Solutions, Inc., the exclusive provider of advanced sorbent hemodialysis products and services for treatment of patients with renal failure, announced today that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its newly enhanced Allient(R) Sorbent Hemodialysis System in chronic and acute hemodialysis applications. The new Allient System features improvements in ease of manufacturing, service and user-friendliness. In preparation for the Allient System commercialization, Renal Solutions is also launching its SMARRT(TM) (Sorbent Management for Advanced Renal Replacement Therapy) platform and campaign, which will introduce the benefits of advanced sorbent therapy to the renal community.

SMARRT therapy utilizes a gentle, patient-driven technology backed by over 6 million treatments. It enables short, standard or extended duration hemodialysis therapy using just 1.5 gallons (6 liters) of drinking water. The small dialysate quantity made possible by sorbent technology provides an inherent volume safety not possible with conventional hemodialysis technology. At the same time, it creates a dialysate flow rate of up to 400 ml/min., enabling the provision of highly effective dialysis. Advanced sorbent cartridges contain specialized sorbent compounds that regenerate fresh, high purity dialysate, eliminating the need for complex and costly water purification systems.

The Allient System will be the first dialysis system to bring SMARRT technology to the market, opening new treatment options to dialysis professionals and patients. The Allient System provides multiple treatment options without the need for an independent water purification system, batch production of dialysate, or large volumes of packaged sterile fluid. In addition to the sorbent cartridge benefits, the Allient System's revolutionary Pulsar(TM) Blood Pump provides expanded safety and versatility advantages as compared to conventional pumps. Through its unique, pressure-limited, two-chamber design, the Pulsar Pump enables both dual and single needle access. Pressure limitation, in combination with single needle access, provides added safety against vascular access disconnection, as well as a diminished risk of vascular access trauma.

"Renal Solutions is very excited to introduce the newly designed Allient System and SMARRT Therapy to the hemodialysis market," said Peter M. DeComo, Chairman and CEO of Renal Solutions. "The inherent benefits of a therapy that requires so little water are readily apparent and represent the dialysis technology of the future."

"We're enthusiastic about the options that the Allient System and SMARRT therapy bring to our practice and to the renal world," said Derrick L. Latos, MD, MACP, Medical Director, Wheeling Renal Care, W.V. and Medical Director of Renal Solutions. "The ability to provide flexible treatments in a wide range of treatment environments and the freedom from the hassles of having to provide a complex and expensive water purification system are very attractive benefits to healthcare providers looking to improve the quality of patient care."

About Renal Solutions, Inc

Renal Solutions, Inc., a medical device and healthcare service company, is commercializing the Allient(R) Sorbent Hemodialysis System, a revolutionary technology/service solution for the chronic and acute dialysis market. The Allient System, brings SMARRT (Sorbent Management for Advanced Renal Replacement Therapy) therapy to the dialysis field, opening new treatment options to dialysis professionals and patients by virtue of its ability to provide short, standard or extended duration hemodialysis therapy using just 1 and 1/2 gallons of ordinary drinking water. Numerous clinical studies have shown that an increased cumulative dialysis dose results in better patient outcomes. The Allient System provides the increased dose advantage without the need for an independent water system or large volumes of sterile fluid. This translates into increased flexibility and convenience benefits.

http://www.renalsolutionsinc.com


'/>"/>
SOURCE Renal Solutions, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Renal problem alleviated
2. Increase in renal problems
3. Effect of drug on Renal Cancer
4. Renal problem increased
5. Drug Spironolactone Provides Renal And Cardioprotection In Diabetic Patients
6. Acute Toxicity Of Nano-Scale Zinc Powder: Severe Renal Damage And Anemia
7. A Novel Method Of Detection Of High Nuclear Grade Localized Renal Cell Carcinoma
8. Negative Impact Of Hepatitis C Infection In Renal Transplant Recipients
9. Clinical Renal Trails Do Not Have Sufficient Women Participants
10. Adrenal Suppression not predicted by inhaled corticosteroids
11. Sunitinib a Promising Agent for Treatment of Renal Cell Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/20/2017)... NY (PRWEB) , ... January 20, 2017 , ... ... VW+ 001 and its sugar-free alternative VW+ 002. The drinks have been produced ... with optimal conditions to perform during your workout. , After a successful launch ...
(Date:1/20/2017)... ... January 20, 2017 , ... “I Forgive You”: a fine examination of how God ... is the creation of published author, Stephen Miller, who, for over ten long years has ... to him. Born in Trinidad and Tobago, he has been serving the Lord for over ...
(Date:1/20/2017)... ... , ... “Knowledge is God’s Lighthouse”: a moving and colorful collection of ... the creation of published author, Gene Gaapf, a retired truck driver, and a long-time ... been writing since high school and have many different titles,” Gaapf mentions about his ...
(Date:1/19/2017)... ... January 19, 2017 , ... ... Management System: an On-demand E-learning system for Clinical and Regulatory education for ... is based on Aerolib`s successful education methodology of Disease Specific Documentation Improvement. ...
(Date:1/19/2017)... ... 19, 2017 , ... This month, the CEO and Clinical Director of Sober ... rehab center in Delray Beach, Florida has been changed from Sober Living Outpatient to ... Philip Seymour Hoffman and Chris Farley are dying from heroin overdoses, but thousands of ...
Breaking Medicine News(10 mins):
(Date:1/19/2017)... and Webcast to Follow Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: ... the fourth quarter of 2016 on Wednesday, February 15, 2017, after ... ... on Wednesday, February 15, 2017, during which management will discuss the ... activities. To participate in the conference call, please dial 1-888-771-4371 (domestic) ...
(Date:1/19/2017)... , Jan. 19, 2017 This report ... current and future scenario of the global market. Large ... opioid consumption. Severe chronic constipation is a major side ... traditional laxatives. Hence, novel targeted therapy has been prescribed ... sufferers, launch of targeted medicines, and growing awareness about ...
(Date:1/19/2017)... BioTherapeutics Inc. ( Stealth ), a clinical-stage biopharmaceutical company ... additions to its senior leadership team: W. Douglas ... Daniel Geffken as interim Chief Financial Officer. In ... has been promoted to Chief Clinical Development Officer. ... Daniel to our management team, as both will be ...
Breaking Medicine Technology: